Spain is experiencing ongoing disruptions in pharmaceutical supply, and the latest alert from the Spanish Agency of Medicines and Medical Devices (AEMPS) concerns a widely used antibiotic. A specific formulation of amoxicillin/clavulanic acid will be unavailable for several months, adding to a growing list of medications facing shortages across the country. This situation highlights the fragility of pharmaceutical supply chains and the challenges in ensuring consistent access to essential medicines.
The affected product is Amoxicilina/Ácido Clavulánico Cinfa 875 mg/125 mg powder for oral suspension in sachets, a generic medication manufactured by Laboratorios Cinfa S.A. While this particular presentation is experiencing a supply gap, the AEMPS assures the public that the overall supply of amoxicillin/clavulanic acid remains guaranteed. Pharmacists are able to substitute the affected presentation with equivalent brands or generic alternatives containing the same active ingredients and dosage, minimizing disruption for patients.
Supply Disruption Details
The supply issue officially began on March 6, 2026, and is currently projected to last for nearly three months. The AEMPS anticipates a return to normal supply levels by May 29, 2026. This timeline is based on information provided by the agency, led by María Jesús Lamas, and aims to provide clarity for healthcare professionals and patients alike. The AEMPS regularly communicates these types of supply issues, reflecting a broader trend of pharmaceutical shortages in Spain.
Understanding Amoxicillin/Clavulanic Acid
Amoxicillin/clavulanic acid is a combination antibiotic used to treat a variety of bacterial infections. It contains two active ingredients: amoxicillin, a penicillin-family antibiotic, and clavulanic acid. The clavulanic acid plays a crucial role by preventing bacteria from inactivating the amoxicillin, thereby enhancing the antibiotic’s effectiveness against resistant microorganisms. This combination is commonly prescribed for infections affecting the respiratory tract, urinary tract, and skin.
The typical adult dosage involves taking one sachet two or three times daily, ideally at the start of meals to improve stomach tolerance.
The AEMPS, as a public agency attached to the Ministry of Health, is responsible for guaranteeing the quality, safety, and efficacy of medicines throughout their lifecycle, as stated on their official website. Learn more about the AEMPS mission and values. The agency likewise oversees the evaluation, authorization, and monitoring of pharmaceuticals, medical devices, cosmetics, and other health products. You can identify more information about medicine registration procedures on the AEMPS website.
The ongoing issues with drug supply are not unique to this antibiotic. The AEMPS communicates, on a near-daily basis, about drug supply problems in Spain, affecting a wide range of products.
As the situation evolves, it’s vital for patients to consult with their healthcare providers and pharmacists regarding appropriate treatment options. The AEMPS continues to monitor the supply chain and perform towards resolving these disruptions to ensure continued access to essential medications for the Spanish population.
Disclaimer: This article provides informational content only and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
What are your thoughts on the ongoing pharmaceutical supply issues? Share your experiences and concerns in the comments below.
